EA200500210A1 - Конъюгаты стероидов, их получение и их применение - Google Patents
Конъюгаты стероидов, их получение и их применениеInfo
- Publication number
- EA200500210A1 EA200500210A1 EA200500210A EA200500210A EA200500210A1 EA 200500210 A1 EA200500210 A1 EA 200500210A1 EA 200500210 A EA200500210 A EA 200500210A EA 200500210 A EA200500210 A EA 200500210A EA 200500210 A1 EA200500210 A1 EA 200500210A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugates
- application
- receiving
- taxol
- steroid conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Раскрыты конъюгаты, включающие один или более стероидов, конъюгированных с одним или более белками млекопитающих. Конъюгаты можно применять для диагностики или лечения солидной раковой опухоли и гематологических злокачественных заболеваний. Кроме того, конъюгаты проявляют синергическое действие вместе с препаратом, действующим на клеточный каркас, таким как таксол, что обеспечивает возможность лечения раковых опухолей, которые иначе не реагировали бы на таксол.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20020100335 | 2002-07-16 | ||
PCT/IB2003/002785 WO2004006966A1 (en) | 2002-07-16 | 2003-07-14 | Steroid conjugates, preparation thereof and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200500210A1 true EA200500210A1 (ru) | 2005-06-30 |
Family
ID=36441275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500210A EA200500210A1 (ru) | 2002-07-16 | 2003-07-14 | Конъюгаты стероидов, их получение и их применение |
Country Status (7)
Country | Link |
---|---|
US (2) | US7358379B2 (ru) |
AU (1) | AU2003281165B2 (ru) |
BR (1) | BR0312690A (ru) |
CA (1) | CA2492297A1 (ru) |
EA (1) | EA200500210A1 (ru) |
MX (1) | MXPA05000615A (ru) |
PL (1) | PL375363A1 (ru) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215102A (en) | 1979-01-05 | 1980-07-29 | Lee Sin H | Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues |
NZ196126A (en) | 1980-02-07 | 1985-05-31 | Commw Scient Ind Res Org | Increasing ovulation rate in female cattle |
US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5834213A (en) | 1991-05-02 | 1998-11-10 | Baylor College Of Medicine | Screening system and assay for identifying compounds that regulate steroid and orphan receptors mediation of DNA transcription |
WO1993002691A1 (en) | 1991-08-09 | 1993-02-18 | Mount Sinai School Of Medicine Of The City University Of New York | Steroid hormone drug delivery |
US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
CA2330611A1 (en) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and therapies based thereon |
US6416737B1 (en) * | 1998-11-19 | 2002-07-09 | Board Of Trustees Of The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
EP1104667A1 (en) | 1999-11-29 | 2001-06-06 | The Procter & Gamble Company | Disposable absorbant article having fecal management layer |
NO314537B1 (no) | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
GB0010683D0 (en) | 2000-05-03 | 2000-06-28 | Univ Bristol | Cancer therapy |
HU229207B1 (en) * | 2000-09-14 | 2013-09-30 | Univ British Columbia | Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine regulated tumor therapy |
US7199115B2 (en) * | 2004-04-19 | 2007-04-03 | Schering Ag | 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them |
-
2003
- 2003-07-14 EA EA200500210A patent/EA200500210A1/ru unknown
- 2003-07-14 MX MXPA05000615A patent/MXPA05000615A/es not_active Application Discontinuation
- 2003-07-14 AU AU2003281165A patent/AU2003281165B2/en not_active Ceased
- 2003-07-14 PL PL03375363A patent/PL375363A1/xx not_active Application Discontinuation
- 2003-07-14 CA CA002492297A patent/CA2492297A1/en not_active Abandoned
- 2003-07-14 BR BR0312690-0A patent/BR0312690A/pt not_active Application Discontinuation
-
2006
- 2006-04-04 US US11/398,022 patent/US7358379B2/en not_active Expired - Fee Related
-
2008
- 2008-03-28 US US12/058,375 patent/US20080267875A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7358379B2 (en) | 2008-04-15 |
AU2003281165B2 (en) | 2006-08-03 |
PL375363A1 (en) | 2005-11-28 |
US20060178295A1 (en) | 2006-08-10 |
US20080267875A1 (en) | 2008-10-30 |
AU2003281165A1 (en) | 2004-02-02 |
BR0312690A (pt) | 2005-05-03 |
MXPA05000615A (es) | 2005-11-17 |
CA2492297A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100111A1 (ru) | Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами | |
WO2004058171A3 (en) | Antibodies against gpr64 and uses thereof | |
HK1120427A1 (en) | Anti-glypican-3 antibody | |
WO2006020722A3 (en) | Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting | |
BR0112111A (pt) | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina | |
SG170080A1 (en) | Human monoclonal antibodies to o8e | |
EA200701448A1 (ru) | Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного | |
SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
WO2004031411A3 (en) | Genes and polypeptides relating to human pancreatic cancers | |
ATE206395T1 (de) | Fluoreszierende porphyrin- und fluoreszierende phthalocyanin-polyethylenglykol-, polyol- und saccharidderivate als fluoreszierende sonden | |
PL343462A1 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor | |
EA200501206A1 (ru) | Производные от сурвивина пептиды и их применение | |
HK1071066A1 (en) | Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment | |
EA200800268A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ | |
EA200800094A1 (ru) | Антитела cd19 и их использование | |
TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
BR0109266A (pt) | Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto | |
BRPI0509177A (pt) | uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas | |
UY26929A1 (es) | Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis | |
BR0010702A (pt) | Novas quinonas como terapias de doenças | |
ATE442861T1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
HK1116186A1 (en) | Azaxanthones and use thereof for treating tumors | |
HK1033910A1 (en) | Use of erythropoietin in the treatment of multiple myeloma | |
WO2007149586A3 (en) | Anti-c35 antibodies for treating cancer | |
IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer |